Welcome to our dedicated page for Regenerative Medical Technology Group news (Ticker: RMTG), a resource for investors and traders seeking the latest updates and insights on Regenerative Medical Technology Group stock.
Regenerative Medical Technologies Group, Inc. (RMTG) is a regenerative medicine company in the healthcare and biotechnology space, operating globally through its Global Stem Cells Group subsidiary. The RMTG news feed on Stock Titan highlights how the company combines stem cell and cellular therapies, biologic manufacturing, and physician education to build its presence in more than 30 countries.
News coverage for RMTG often focuses on international expansion and affiliate agreements, such as representation and partnership deals in Puerto Rico, northern Argentina and Paraguay, Brazil, and the Dominican Republic. These stories describe how local medical leaders are appointed to develop regional centers, training programs, and product distribution networks under the Global Stem Cells Group and ISSCA brands.
Another major theme in RMTG news is education and training events. Press releases detail ISSCA summits and in-country programs that bring together physicians and scientists for lectures, hands-on workshops, and certification in regenerative medicine protocols. These events generate revenue through registration fees, certification programs, exhibitor opportunities, and product sales, and they showcase the company’s CELLGENIC product line and manufacturing capabilities.
RMTG news also covers manufacturing developments and strategic partnerships, including the soft opening of an advanced cell therapy manufacturing facility in Cancún, Mexico, and a partnership with Bare Knuckle Fighting Championship to provide stem cell and regenerative treatments for fighters’ injuries. Financial updates, such as year-over-year sales growth and operating income, appear in earnings-related press releases.
Investors and healthcare professionals can use the RMTG news page to follow updates on geographic expansion, new affiliates, education initiatives, manufacturing milestones, and business performance as disclosed by the company.
Regenerative Medical Technology Group (OTCID:RMTG) announced that its Cellgenic division has introduced a multilineage-differentiating stress-enduring (MUSE) cell product line for selected international markets, including Latin America, the Middle East, Europe, and Southeast Asia, subject to local regulatory requirements. MUSE cells are pluripotent-like stem cells identified in adult tissue and studied for stress tolerance and multilineage differentiation. The launch follows Cellgenic’s August 24, 2026 introduction of a Natural Killer (NK) cell product line, reflecting a strategy of sequential, technology-specific product rollouts to expand Cellgenic’s advanced cellular-technology portfolio and support a repeatable product-development and market-entry model. The company states it is not making therapeutic claims in this announcement.
Regenerative Medical Technology Group (OTC:RMTG), a regenerative medicine company operating through Global Stem Cells Group, announced it has acquired the RMTG.com domain and launched a new investor-focused corporate website at that address. According to Regenerative Medical Technology Group, the new site is intended to be the central, easily accessible hub for investor communications, corporate information, and public disclosures, with the web address now matching the company’s stock ticker symbol.
The RMTG.com site consolidates company news, press releases, links to SEC and OTC Markets filings, corporate overview materials, and investor-relations contact information. RMTG stated that this launch is part of a broader initiative to enhance transparency, including its first investor conference call, and that investor inquiries should now be directed to ir@rmtg.com. The company emphasizes that SEC filings remain the authoritative information source.
Regenerative Medical Technology Group (OTCID:RMTG) announced the launch of a new Natural Killer (NK) cell product line through its Cellgenic division for permitted markets outside the United States, initially targeting Latin America and Southeast Asia.
The NK cell platform extends RMTG's cellular-technology portfolio into immunology-adjacent applications. The products are aimed at physicians and clinics operating under local regulatory frameworks and are offered without therapeutic claims that would require additional regulatory support. According to RMTG, this launch fits its strategy of using product-line introductions to convert research, sourcing, and manufacturing capabilities into near-term commercial opportunities in international markets.
Regenerative Medical Technology Group (OTC: RMTG) reported record Q2 2026 revenue of $4,022,763, up 309% year over year and over 50% sequentially, with gross profit of $2,578,171 and approximately 64% gross margin. Operating income reached $565,977, versus a prior-year operating loss of $(250,087).
According to RMTG, growth was led by its ISSCA training division, where revenue rose 860% to $1,295,588, and Cellgenic product supplies, up 421% to $2,103,181. Patient procedures revenue increased 42% to $620,493. For H1 2026, revenue was $6,662,116 (up 184% year over year) with gross profit of $4,344,662 and roughly 65% margin. The company ended Q2 with about $1.3 million in cash and highlighted its growing Affiliate membership program and a clinic network in more than 30 countries.
Regenerative Medical Technology Group (OTCID:RMTG) announced details for its inaugural investor call addressing shareholder-submitted questions, following what it describes as a strong first half of 2026. Management will deliver prepared remarks without a live Q&A or discussion of second quarter 2026 financial results.
Event: RMTG Investor Call – Shareholder Questions. Date: Thursday, August 20, 2026. Time: 5:00–6:00 p.m. Eastern Time (America/New York). Format: Google Meet video call via the published link. According to RMTG, further updates on growth initiatives and operating performance will follow in subsequent releases, and investors are encouraged to review filings on the SEC website.
Regenerative Medical Technology Group (OTC:RMTG) announced an expansion of its Cellgenic division’s flagship laboratory in Cancún, Mexico, adding two ISO 7-classified clean rooms to its existing infrastructure. The owned-infrastructure investment is designed to increase manufacturing capacity, product-development throughput, and quality-systems capability for Cellgenic’s growing international portfolio, including NK cell, MUSE, and peptide-delivery technologies.
According to Regenerative Medical Technology Group, the Cancún expansion is a key element of its long-term international growth strategy and aligns Cellgenic’s laboratory footprint with Cellular Hope Institute’s clinical presence in the same city, supporting current production and future product-line development.
Regenerative Medical Technologies Group (OTC:RMTG) plans to hold its first-ever investor call within the next two weeks to discuss what it describes as significant positive results expected in its upcoming Q2 2026 filing. The initiative is positioned as a milestone in shareholder engagement and transparency.
According to RMTG, Q1 2026 delivered record results: revenue of $2,639,353, up 93% year over year; gross profit of $1,766,491, up 87%; and operating income of $229,783, up 70%. Growth was led by the ISSCA training division, Cellgenic product supply, and recurring Affiliate membership revenue across a clinic network in more than 30 countries. Investors can submit questions via email this week, with a follow-up release to provide the call’s exact date, time, and dial-in details.
Regenerative Medical Technology Group (OTC:RMTG), through subsidiary Global Stem Cells Group and its Cellgenic division, announced the launch of Cellgenic’s regulated commercial operations in Argentina, establishing a strategic hub for regenerative medicine in Latin America. Following completion of regulatory and operational milestones, Cellgenic can commercialize qualifying biologic and regenerative medicine products via licensed medical practitioners in compliance with Argentine regulations.
Cellgenic plans to expand its sales force, run physician education conferences and certification programs with ISSCA, develop new clinical collaborations and case studies, and broaden distribution across Argentina and neighboring Latin American markets, positioning Argentina as a primary regional center within RMTG’s global regenerative medicine ecosystem.
Regenerative Medical Technologies Group (OTC:RMTG) launched the ISSCA AI™ Clinical Intelligence Platform, an AI system supporting regenerative and longevity medicine workflows. Built on a 30+ country physician network, millions of historical patient records, and the ISSCA Mobile App, it targets intake, protocols, predictive modeling, operations, and patient engagement, with plans to integrate education, biologics (CELLGENIC), and digital tools into a connected clinical ecosystem.
Global Stem Cells Group (OTC:RMTG) launched the physician-facing ISSCA Mobile App, created by its training arm ISSCA. The app digitizes a physician network spanning 30+ countries and centralizes regenerative and longevity medicine education, certifications, webinars, and collaboration, forming a scalable digital ecosystem and future base for ISSCA AI™.